PT - JOURNAL ARTICLE AU - Wang, Ziyue AU - Farztdinov, Vadim AU - Sinn, Ludwig Roman AU - Tober-Lau, Pinkus AU - Ludwig, Daniela AU - Freiwald, Anja AU - Amari, Fatma AU - Textoris-Taube, Kathrin AU - Niewienda, Agathe AU - Welter, Anna Sophie AU - Wei, Alan An Jung AU - Luckau, Luise AU - Kurth, Florian AU - Selbach, Matthias AU - Hartl, Johannes AU - Mülleder, Michael AU - Ralser, Markus TI - Cross-platform Clinical Proteomics using the Charité Open Standard for Plasma Proteomics (OSPP) AID - 10.1101/2024.05.10.24307167 DP - 2024 Jan 01 TA - medRxiv PG - 2024.05.10.24307167 4099 - http://medrxiv.org/content/early/2024/05/10/2024.05.10.24307167.short 4100 - http://medrxiv.org/content/early/2024/05/10/2024.05.10.24307167.full AB - The role of plasma and serum proteomics in characterizing human disease, identifying biomarkers, and advancing diagnostic technologies is rapidly increasing. However, there is an ongoing need to improve proteomic workflows in terms of accuracy, reproducibility, platform transferability, and cost-effectiveness. Here, we present the Charité Open Peptide Standard for Plasma Proteomics (OSPP), a panel of 211 extensively pre-selected, stable-isotope labeled peptides combined in an open, versatile, and cost-effective internal standard for targeted and untargeted plasma and serum proteomics studies. The selected peptides show consistent quantification properties in human studies, across platforms and matrices, are well suited for chemical synthesis, and distribute homogeneously over proteomics-typical chromatographic gradients. Being derived from proteins that function in a wide range of biological processes, including several that are routinely used in clinical tests or are targets of FDA-approved drugs, the OSPP quantifies proteins that are important for human disease. On an acute COVID-19 in-patient cohort, we demonstrate the application of the OSPP to i) achieve patient classification and biomarker identification, ii) generate comparable quantitative proteome data with both targeted and untargeted proteomic approaches, and iii) estimate absolute peptide quantities to achieve cross-platform alignment across targeted, data-dependent and data-independent acquisition (DIA) proteomic methods on different instrument platforms. The OSPP adds only cents of cost per proteome sample, thus making the use of an internal standard cost-effective and accessible. In addition to the standards, corresponding spectral libraries and optimized acquisition methods for several platforms are made openly available.Competing Interest StatementMarkus Ralser is founder and shareholder, while Michael Muelleder and Ziyue Wang are advisors, and Luise Luckau is an Employee of Elitpca. Ltd.Funding StatementThis work was supported by the Ministry of Education and Research (BMBF), as part of the National Research Node Mass Spectrometry in Systems Medicine (MSCoreSys), under grant agreements 16LW0239K (to M.M.), 01EP2201 (to M.R.), the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) 492697668 and the European Research Council (ERC SyG-2020 951475). This work was further supported by a BIH Booster Grant (2022-B3020086-11/12 to Z.W., P.T-L., F.K., J.H. M.M, M.R.) and DKTK under grant agreement BE01 1020000483. Z.W. is a member of the International Max Planck Research School (IMPRS) for Infectious Diseases and Immunology, and the Deutsche Forschungsgemeinschaft (DFG) funded Sonderforschungsbereich (SFB) TRR 186.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The COVID-19 cohort is a subcohort of the Pa-COVID-19 study, which is carried out according to the Declaration of Helsinki and the principles of Good Clinical Practice (ICH 1996) where applicable and was approved by the ethics committee of Charite- Universitaetsmedizin Berlin (EA2/066/20).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes